RDMD raises $14M for rare disease real-world evidence generation
The San Francisco-based startup is one of several that have been raising money over the past couple of weeks in areas like neurology, oncology and women's health.
Obesity drug lorcaserin gets thumbs-down from FDA (Morning Read)
The Food and Drug Administration made it official Saturday, turning a thumbs-down to Lorqess (lorcaserin), the new diet drug by Arena Pharmaceuticals, because of concerns that it may cause tumors in rats and is marginally effective, according to the Pharmalot blog.
presented by
Survey on the Healthcare Financial Landscape Offers a Roadmap for Stakeholders
Zelis highlights how employers, payers, and consumers are integrating digital tools to manage healthcare costs.